Issued to HQ Specialty Pharma Corporation. Application reviewed but not approved; deficiencies must be corrected.
Issued
September 14, 2021Application
NDA 505b1 • 215212
Product
MEROPENEM
Company
HQ Specialty Pharma Corporation
Review center
Other
Stage
Final Decision
Response due
December 31, 2024
Assyro regulatory brief
FreeSource facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
FDA's complete response letter contains source-text evidence related to Labeling, packaging, and proprietary name, Safety and adverse events, Nonclinical evidence. Theme counts identify where the letter discusses a topic; they do not replace review of the exact redacted letter.
Review the exact redacted FDA letter and address each stated deficiency before resubmission.
Open the document workspaceFDA source document
Application reviewed but not approved; deficiencies must be corrected. Requires resubmission addressing deficiencies. FDA issued this letter to HQ Specialty Pharma Corporation on September 14, 2021.
NDA 215212 is the application under which FDA issued this complete response letter for MEROPENEM to HQ Specialty Pharma Corporation. It was reviewed by FDA Other. The letter is dated September 14, 2021.
FDA will not approve the application in its present form. The sponsor can resubmit after addressing every deficiency listed in the letter — which starts a Class 1 (two-month) or Class 2 (six-month) resubmission review clock — withdraw the application, or request an opportunity for a hearing.